Diminished Short-Term Efficacy of Reduced-Dose Induction BCG in the Treatment of Non-Muscle Invasive Bladder Cancer

Diminished Short-Term Efficacy of Reduced-Dose Induction BCG in the Treatment of Non-Muscle Invasive Bladder Cancer

The ongoing Bacillus Calmette-Guérin (BCG) shortage has created challenges for the treatment of non-muscle invasive bladder cancer (NMIBCa). Our objective was to evaluate the efficacy of reduced-dose induction BCG (RD-iBCG) compared to full-dose induction BCG (FD-iBCG) regarding recurrence rates. We...

Full description

Bibliographic Details
Main Authors:	David A. Ostrowski, Raju R. Chelluri, Matthew Herzig, Leilei Xia, Brian D. Cortese, Daniel S. Roberson, Thomas J. Guzzo, Daniel J. Lee, S. Bruce Malkowicz
Format:	Article
Language:	English
Published:	MDPI AG 2023-07-01
Series:	Cancers
Subjects:	BCG shortage reduced dose bacillus Calmette-Guérin non-muscle invasive bladder cancer
Online Access:	https://www.mdpi.com/2072-6694/15/14/3746

Similar Items

Disseminated BCG sepsis following intravesical therapy for Bladder Carcinoma: A case report and review of literature
by: Oreoluwa Oladiran, et al.
Published: (2020-03-01)

Immunological Hallmarks for Clinical Response to BCG in Bladder Cancer
by: Chun Jye Lim, et al.
Published: (2021-01-01)

Asymptomatic renal BCG granulomatosis: An unusual complication of intravesical BCG therapy for carcinoma urinary bladder
by: Suresh Bhat, et al.
Published: (2015-01-01)

Carcinoma In Situ (CIS): Is There a Difference in Efficacy between Various BCG Strains? A Comprehensive Review of the Literature
by: Andres Llano, et al.
Published: (2024-01-01)

Bacillus Calmette–Guérin and Bladder Cancer
by: Azad H.A. Razack
Published: (2007-10-01)

The impact of Bacillus Calmette-Guérin (BCG) vaccination on the course of COVID-19
by: Jakub Krzysztof Gałązka
Published: (2022-10-01)

Case Report with Systematic Literature Review on Vascular Complications of BCG Intravesical Therapy for Bladder Cancer
by: Brianna King, et al.
Published: (2022-10-01)

Vaccination-related Mycobacterium bovis BCG Infection
by: Anna Liberek, et al.
Published: (2006-05-01)

NFκB-Activated COX2/PGE<sub>2</sub>/EP4 Axis Controls the Magnitude and Selectivity of BCG-Induced Inflammation in Human Bladder Cancer Tissues
by: Omar M. Ibrahim, et al.
Published: (2021-03-01)

Antibiotic therapy impact on intravesical BCG therapy efficacy for high-risk localized bladder cancer treatment
by: Cécile Aubert, et al.
Published: (2024-03-01)

A randomized trial comparing low dose (40 or 80 mg) with standard dose (120 mg) of bacillus Calmette-Guerin for superficial bladder cancer
by: Vivek Vijjan, et al.
Published: (2006-01-01)

Impact of intravesical Bacillus Calmette-Guérin and chemotherapy on the bladder microbiome in patients with non-muscle invasive bladder cancer
by: Christopher James, et al.
Published: (2023-04-01)

Effects of acupuncture to decrease adverse events in patients with high-risk non-muscle invasive bladder cancer receiving induction intravesical BCG therapy: Study protocol for a randomized, controlled pilot and feasibility study
by: Sarah P. Psutka, et al.
Published: (2022-12-01)

Grupo Técnico de Estudos do BCG em Câncer Vacina BCG (Bacillus Calmette-Guérin)
by: Humberto Torloni, et al.
Published: (2023-08-01)

A single strain of Mycobacterium bovis bacillus Calmette-Guérin (BCG) grown in two different media evokes distinct humoral immune responses in mice
by: V.L. Petricevich, et al.
Published: (2001-01-01)

BCG induced lower urinary tract symptoms during treatment for NMIBC—Mechanisms and management strategies
by: Georgia Bourlotos, et al.
Published: (2024-01-01)

A case of post-BCG therapy renal granuloma concurrent with ureteral carcinoma
by: Tatsuya Otaki, et al.
Published: (2023-03-01)

Association Between Antibiotic Treatment and the Efficacy of Intravesical BCG Therapy in Patients With High-Risk Non-Muscle Invasive Bladder Cancer
by: Sahyun Pak, et al.
Published: (2021-04-01)

Urethral fistula and perineal collection during intravesical treatment for non-muscle invasive bladder cancer – A rare complication
by: Katherine Ong, et al.
Published: (2022-05-01)

From Interferon to Checkpoint Inhibition Therapy—A Systematic Review of New Immune-Modulating Agents in Bacillus Calmette–Guérin (BCG) Refractory Non-Muscle-Invasive Bladder Cancer (NMIBC)
by: Susanne Deininger, et al.
Published: (2022-01-01)

Perianal Plasmoacanthoma After BCG-Immunotherapy: Case Report and Review of Literature
by: Masoumeh Roohaninasab, et al.
Published: (2022-07-01)

Systematic Review and Meta-Analysis of Response Rates in BCG-unresponsive Non–Muscle-Invasive Bladder Cancer: a Consensus Statement From the International Bladder Cancer Group
by: Kyle M. Rose, et al.
Published: (2022-09-01)

Single course of intravesical Bacillus Calmette–Guerin versus single course with maintenance therapy in the management of nonmuscle invasive bladder cancer: A prospective randomized study
by: Mohamed Bakr Mohamed, et al.
Published: (2020-01-01)

The safety of BCG revaccination in the context of COVID-19
by: Adriana Sánchez-García, et al.
Published: (2023-12-01)

Emerging concepts and spectrum of renal injury following Intravesical BCG for non-muscle invasive bladder cancer
by: Azharuddin Mohammed, et al.
Published: (2017-12-01)

Intravesical Bacillus Calmette-Guérin (BCG) treatment's severe complications: A single institution review of incidence, presentation and treatment outcome
by: R. Waked, et al.
Published: (2020-05-01)

Granulomatous Hepatitis Following Intra-Vesical Instillation of Bacillus Calmette–Guérin for Treatment of Bladder Cancer
by: Elsa Alves Branco, et al.
Published: (2021-07-01)

Disseminated Bacillus Calmette–Guérin (BCG) infection and acute exacerbation of interstitial pneumonitis: an autopsy case report and literature review
by: Gen Shimizu, et al.
Published: (2020-09-01)

Weekly intravesical bacillus Calmette-Guerin (BCG) alternating with epirubicin in Ta and T1 urothelial bladder cancer: An approach to decrease BCG toxicity
by: Bedeir Ali-El-Dein, et al.
Published: (2013-01-01)

Impact of Reducing Irritative Symptoms in Non-Muscle Invasive Bladder Cancer During BCG Instillation: A Pilot Study
by: Osman Köse, et al.
Published: (2020-12-01)

Severe Respiratory Failure Due to Pulmonary BCGosis in a Patient Treated for Superficial Bladder Cancer
by: Katarzyna Lewandowska, et al.
Published: (2022-04-01)

Intravesical bacillus Calmette-Guerin (BCG) in treating non-muscle invasive bladder cancer—analysis of adverse effects and effectiveness of two strains of BCG (Danish 1331 and Moscow-I)
by: Yuvaraja B. Thyavihally, et al.
Published: (2022-04-01)

The Diverse Applications of Recombinant BCG-Based Vaccines to Target Infectious Diseases Other Than Tuberculosis: An Overview
by: Esma Mouhoub, et al.
Published: (2021-10-01)

Tuberculous epididymo-orchitis secondary to Bacillus Calmette-Guérin (BCG) in non-muscular invasive bladder cancer
by: Luis Felipe Lara Moscoloni, et al.
Published: (2021-07-01)

Mycobacterium bovis Osteomyelitis of the Thoracic Spine Mimicking a Metastatic Lytic Lesion in a Patient Exposed to Intravesicular Bacille Calmette-Guérin Treatment
by: Jessica R. Newman, et al.
Published: (2014-07-01)

Breast abscess due to Bacillus Calmette-Guérin
by: Aurélien Dinh, et al.
Published: (2017-06-01)

Intravesical Bacillus Calmette–Guérin Treatment for T1 High-Grade Non-Muscle Invasive Bladder Cancer with Divergent Differentiation or Variant Morphologies
by: Makito Miyake, et al.
Published: (2021-05-01)

Bacillus Calmette-Guerin Increases Base Excision Repair in Bladder Cancer Cells
by: Selçuk Keskin, et al.
Published: (2021-03-01)

Intravesical ALT-803 for BCG-unresponsive Bladder Cancer – A Case Report
by: Jeffrey Huang, et al.
Published: (2017-09-01)

Regression of the Sweet's syndrome after Bacillus Calmette-Guérin therapy: A bladder cancer case report
by: İbrahim Halil Baloglu, et al.
Published: (2020-07-01)